Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study

RCT (n=1,890) found after 52 weeks treatment, fremanezumab administered monthly or quarterly reduced monthly migraine days in both chronic and episodic migraine. Most commonly reported adverse effects were injection site reactions (induration [33%] pain [31%] and erythema [26%]).

Source:

Neurology